BUY NOVOSARM – STENABOLIC (SR9009) (50 MG/ML – 30 ML)
MAIN PRODUCT DESCRIPTION
NovoSARM – Stenabolic (SR9009) 50 mg/ml contains SR9009, an investigational small molecule that has been studied for its interaction with the REV-ERB family of nuclear receptors. The supplied information describes SR9009 in relation to metabolic regulation, energy utilisation, lipid metabolism and endurance-related research. The product is presented as a 50 mg/ml liquid preparation in a 30 ml bottle.
SR9009 should not be confused with selective androgen receptor modulators (SARMs). Despite sometimes being marketed alongside SARMs and other research compounds, SR9009 does not act primarily through the androgen receptor. Its proposed mechanism is associated with REV-ERB signalling, making it pharmacologically distinct from compounds such as ostarine, ligandrol or S-23.
Product Specifications
- Product: NovoSARM – Stenabolic
- Alternative name: SR9009
- Strength: 50 mg/ml
- Pack Size: 30 ml
- Active Compound: SR9009
- Pharmacological Target: REV-ERB
- Dosage Form: Liquid preparation
- Route: Not clearly specified in the supplied information
- Regulatory Status: Investigational
- Manufacturer: Not supplied in the source material
REV-ERB and Biological Background
REV-ERB proteins are nuclear receptors involved in the regulation of circadian rhythms and metabolic gene expression. They participate in biological processes affecting lipid metabolism, glucose metabolism, mitochondrial function and cellular energy regulation.
SR9009 has been investigated as a synthetic ligand for REV-ERB. By interacting with this receptor system, researchers have examined whether SR9009 can alter the expression of genes involved in metabolic processes.
The supplied product material describes REV-ERB as a regulator of metabolism, fat storage and cellular processes. However, the biological system is considerably more complex than the simplified description provided in the source, and SR9009 should not be described as simply replacing old cells with “new and better” cells.
Mechanism of Action
The research interest surrounding SR9009 centres on its interaction with REV-ERBα and REV-ERBβ. These proteins act as transcriptional regulators and are involved in controlling the expression of various genes.
Experimental research has examined whether REV-ERB activation can influence metabolic gene networks and mitochondrial-related processes. The supplied information associates SR9009 with changes in energy metabolism, lipid utilisation and cellular activity.
These findings are primarily relevant to laboratory research. They do not establish SR9009 as a treatment for metabolic disease, obesity, muscle loss or impaired physical performance.
Metabolic Research
One of the principal areas of interest for SR9009 is its potential influence on cellular metabolism. Experimental studies have investigated how REV-ERB modulation may alter metabolic pathways involved in energy production and lipid handling.
The supplied source describes SR9009 as promoting fat utilisation and increasing metabolic activity. It also claims that metabolic activity may remain elevated during rest.
These claims should be treated cautiously. Research findings concerning metabolic pathways do not establish that SR9009 produces predictable fat loss or increased metabolic rate in humans.
Mitochondrial Research
The supplied information discusses mitochondria in connection with SR9009 and energy production in skeletal muscle. Mitochondria are cellular organelles responsible for producing much of the body’s usable energy through oxidative metabolism.
REV-ERB signalling has been investigated in relation to mitochondrial function and metabolic regulation. This provides a scientific basis for studying SR9009 in metabolic and exercise-related research.
However, the source does not provide sufficient evidence to establish SR9009 as a clinically proven method of increasing mitochondrial performance or endurance in humans.
Endurance and Exercise Claims
The supplied product information describes SR9009 as a performance-enhancing compound and associates it with increased endurance and exercise-like metabolic effects.
Experimental research has generated interest in whether modulation of REV-ERB signalling can influence exercise-related metabolic adaptations. The source describes research suggesting that SR9009 can produce physiological changes resembling some aspects of exercise in experimental models.
Such findings should not be interpreted as meaning that SR9009 literally reproduces exercise or provides the same health benefits as physical activity.
There is also insufficient evidence supplied here to support claims of guaranteed improvements in endurance, strength or athletic performance.
Body Fat and Muscle Claims
The supplied source promotes SR9009 in connection with fat reduction and muscle development. It describes increased utilisation of stored fat and changes in glucose and lipid metabolism.
These claims reflect the fitness-oriented marketing context of the supplied material. They should not be presented as established therapeutic outcomes.
SR9009 should not be marketed as an approved weight-loss medicine, muscle-building treatment or performance-enhancing pharmaceutical. The supplied information does not establish a validated human dosage or approved indication for these purposes.
Cellular and Macrophage Research
The source discusses macrophages and the removal of damaged or dying cells as part of its explanation of SR9009’s proposed biological effects.
Macrophages are immune cells involved in tissue maintenance, inflammation and clearance of cellular debris. REV-ERB signalling has been studied in relation to macrophage biology and inflammatory pathways.
However, the supplied material’s description of SR9009 causing accelerated removal and replacement of cells should not be interpreted as evidence of general tissue rejuvenation or regeneration in humans.
Regulatory Status
SR9009 is presented in the supplied information as a research compound rather than an approved medicinal product.
No EU marketing authorisation, national marketing authorisation number, approved therapeutic indication or validated prescription status was supplied for this product.
Accordingly, NovoSARM – Stenabolic should not be described as an authorised medicine for obesity, muscle growth, endurance, metabolic disorders or anti-ageing purposes.
Safety Considerations
The supplied source does not provide a comprehensive human safety profile for SR9009. It also does not provide validated long-term safety data, an approved therapeutic dose or a complete contraindication and adverse-reaction profile.
Consequently, the absence of reported side effects in the supplied material should not be interpreted as evidence that SR9009 is safe or free from adverse effects.
The experimental nature of REV-ERB modulation means that potential effects on metabolic, circadian and other biological processes require appropriate scientific evaluation.
Administration Information
The supplied product information identifies a 50 mg/ml, 30 ml liquid preparation but does not provide sufficiently reliable product-specific administration instructions.
No human dosing schedule has therefore been added. Experimental dosing should not be converted into a therapeutic recommendation without appropriate clinical evidence and regulatory authorisation.
Important Research Notice
Stenabolic (SR9009) is an investigational REV-ERB ligand and should not be classified as a conventional SARM or marketed as an approved performance-enhancing medicine.
The supplied information discusses metabolic, mitochondrial, lipid and endurance-related research, but these findings do not establish clinical efficacy, long-term safety or regulatory approval.
This description is based on the product information supplied and should not be interpreted as medical advice, a therapeutic recommendation or instructions for human use.
